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Background and purpose — Patients in Sweden are 
insured against avoidable patient injuries. Prosthetic joint 
infections (PJIs) resulting from intraoperative contamination 
are regarded as compensable by the Swedish public insur-
ance system. According to the Patient Injury Act, healthcare 
personnel must inform patients about any injury resulting 
from treatment and the possibility of fi ling a claim. To ana-
lyze any under-reporting of claims and their outcome, we 
investigated patients’ claims of PJI in a nationwide setting
Patients and methods — The national cohort of PJI after 
primary total hip replacement, initially operated between 
2005 and 2008, was established through cross-matching of 
registers and review of individual medical records. We ana-
lyzed 441 PJIs and the number of fi led patients’ claims, with 
regards to incidence, outcome, and any national, sex-linked 
or socioeconomic differences.
Results — We identifi ed 329/441 (75%) patients with 
PJIs as non-claimants. 96% of the fi led claims were accepted. 
64 (57%) of claimants sustained permanent disability. 2 fac-
tors were found to statistically signifi cantly reduce the odds 
of fi ling claims: patient’s age above 73 years and fracture 
as indication for surgery. There were no signifi cant national, 
sex-linked, or socioeconomic differences.
Interpretation — The incidence of patients’ claims of PJI 
is low but claims are usually accepted when fi led. Healthcare 
personnel should increase their knowledge of the Patient 
Injury Act to inform patients about possibilities of eligible 
compensation.
Everyone treated in Sweden’s publicly fi nanced healthcare is 
insured against injury resulting from avoidable patient injuries. 
Prosthetic joint infections (PJIs) are serious complications and 
may lead to severe consequences for those patients affected. 
PJIs after total hip replacement (THR) surgery, resulting from 
intraoperative contamination and not from hematogenous 
spread, are considered as compensable injuries by the Swed-
ish no-fault insurance system.
During the last decade over 16,500 primary THRs were per-
formed in Sweden each year (Karrholm et al. 2016). A study 
of primary THRs operated between 2005 and 2008 showed 
that the incidence of PJIs in Sweden, up to 2 years after sur-
gery, is 0.9% (Lindgren et al. 2014).
The Swedish Patient Safety Act obligates healthcare person-
nel to inform patients about the possibility of fi ling a mal-
practice claim (SR-PSA 2017). Knowledge of the act varies 
among healthcare personnel (Espersson and Hellbacher 2016). 
Therefore there may be an under-reporting of patient injuries 
and consequently patients are not compensated to the extent 
intended by both the healthcare and legal system.
The aim of this study was to determine the proportion of 
fi led claims and the outcome of these claims (accepted, 
rejected, and disability). We also analyzed any presence of 
national, socioeconomic, age, and sex-linked differences in 
patient claims.
 
The patient insurance scheme in Sweden
Patients’ claims are handled by the national patient insur-
ance company Landstingens Ömsesidiga Försäkringsbolag 
(LÖF), founded in 1975 and co-owned by the 21 Swedish 
county councils (public healthcare). LÖF handles all medi-
cal professions according to the Patient Injury Act (SR-PIA 
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2017) and regardless of the actual healthcare provider being a 
public, county council owned unit or a private division, deliv-
ering healthcare after procurement. The numbers of claims 
are increasing annually and in 2016 LÖF handled 16,000 
claims with almost one-third of reimbursed claims being inju-
ries related to orthopedic procedures (LÖF 2017). Moreover, 
THA is the procedure associated with the highest numbers of 
claims (Pukk-Härenstam et al. 2008). According to conditions 
of insurance, 6 types of injuries are covered, resulting from: 
treatment injury, technical damage, inferior diagnostics, infec-
tion, patient accidents in care, and medication-related injury. 
Patients report their injuries free of charge by completing a 
simple form, which must be fi led within 3 years of injury 
detection but can under certain circumstances be accepted 
up to 10 years after treatment. LÖF then obtains full medi-
cal records before review of claims by specialists with exper-
tise within the medical fi eld concerned. In a case where the 
event was not avoidable and no causative relation or inferior-
ity between given treatment and outcome is observed, LÖF 
can reject a claim. If the opposite is observed, LÖF compen-
sates for the prolonged recovery time or awards payouts for 
sustained permanent disability, in accordance with Insurance 
Sweden consensus tables (IS 2014).
The economic compensation is non-tort, reimbursing 
income loss, unreimbursed medical costs and also includes 
the possibility to recompense for pain and suffering caused by 
the injury. It is also blame-free for practitioners and no records 
are shared with the regulatory authorities. Therefore it is nei-
ther punitive damage compensation nor a sanctioning tool of 
healthcare providers but supplements the extensive coverage 
offered by Swedish social and medical care systems.
Patients and methods
Data collection
This study is based on a previously described population 
(Lindgren et al. 2014) regarding the national incidence of PJI 
after primary THR in Sweden. All patients who had undergone 
a primary THR, between July 1, 2005 December and 31, 2008, 
were initially retrieved from the Swedish Hip Arthroplasty 
Register (SHAR), n = 49,219. Their Swedish personal identi-
fi cation number was used to match patients with the Swedish 
Prescribed Drug Register for continuous outpatient antibiotic 
medication for at least 4 weeks after surgery. The observation 
time was set to 2 years postoperatively to include only early 
and delayed PJIs (Zimmerli and Ochsner 2003). This protocol 
allowed for inclusion of the compensable PJIs, since intraop-
erative contamination occurs within the fi rst 2 years. Simul-
taneously the late appearing PJIs caused by hematogenous 
spread were excluded. No additional selection was made to 
exclude any possible hematogenously spread infections within 
the fi rst 2 postoperative years. Antibiotic treatments with indi-
cations other then PJI were excluded. A questionnaire for each 
of the identifi ed infected 2,217 patients, with long postopera-
tive antibiotic consumption, was sent to the operating units. 
This verifi ed treatment for PJI and the case-specifi c diagnostic 
criteria of PJI, according to the defi nition by the Workgroup 
of the Musculoskeletal Infection Society (Parvizi et al. 2011). 
99% of all questionnaires were returned and Lindgren et al. 
(2014) concluded a fi nal number of 443 treated PJIs. 
Consequently, we could identify 441 PJIs in LISA (the 
national agency Statistics Sweden’s longitudinal integration 
database for health insurance and labor market studies). This 
enabled matching on level of education as a socioeconomic 
factor. Finally, we compared all PJIs with LÖF’s database in 
November 2016 for patients’ claims and outcome of claims 
review. The timeframe was regarded as suffi cient both for 
patients to fi le claims after delayed infections in case of com-
plicated and prolonged PJI treatment and also for LÖF to 
review and conclude its decision.
Study variables
For each patient, we recorded sex, age at primary THR opera-
tion, educational level, treating hospital, and the indication for 
surgery. SHAR divides these indications into 8 groups. Pri-
mary osteoarthritis and hip fracture are the 2 most common 
indications, with apparent different patient characteristics. 
Consequently we analyzed these 2 groups separately. The 
other 6 indications (infl ammatory joint disease, sequel to 
pediatric disease, idiopathic femoral head necrosis, secondary 
osteoarthritis after trauma, malignancy, and other secondary 
osteoarthritis) each consist of fewer patients and are all mainly 
operated in elective settings. They were therefore merged 
together into 1 group, called “other”.
Highest achieved educational level was also grouped, from 
initial 7 levels (elementary school < 9 years, elementary 
school > 9 years, 3 years’ high school, postgraduate < 3 years, 
postgraduate > 3 years, doctoral education, and unknown) to 
4 levels: elementary school, high school, postgraduate, and 
unknown.
To examine any national differences, each operating unit 
was classifi ed according to its location by provision of care 
(the 21 Swedish counties) and separately by order: university 
hospital, referral county hospital, local hospital, and private.
Filed patient claims at LÖF were recorded and their deci-
sions were grouped into 6 outcomes: rejected, prolonged 
recovery (< 3 months and > 3 months), and permanent dis-
ability (1–15%, 16–30%, and > 30%). 
Statistics
The Mann–Whitney U test was used for the age variable in 
independent groups and Pearson’s chi-square test was used for 
nominal variables. Logistic regression analysis was performed 
on patients’ characteristics to evaluate factors associated with 
insurance claims. We used both a univariable and multivari-
able model. The former includes age, sex, diagnosis, and level 
of education, and the latter model consists of age and diag-
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nosis. These 2 factors were verifi ed as statistically signifi cant 
in the univariable model and are simultaneously important in 
a clinical setting. Associations are presented as odds ratios 
(ORs) and risk ratios (RRs) with 95% confi dence intervals 
(CIs). We used IBM SPSS Statistics software (ver. 23) (IBM 
Corp, Armonk, NY, USA).
Ethics, funding, and potential confl icts of interest
The study was conducted in accordance with the Declara-
tion of Helsinki and the protocol was approved by the Ethical 
Review Board in Gothenburg, Sweden (622-16).
We received support from LÖF, in the form of salary sup-
port for PK. LL has previously been involved in LÖF’s expert 
reviews but is not currently committed. There are no other 
confl icts of interest.
Results
329 (75%) of the 441 patients with PJIs did not fi le a claim 
for injury with LÖF. Of those 112 that did, 108 (96%) were 
accepted as eligible for compensation (Table 1). Patients’ age 
above the median of 72 years (OR = 0.4, CI 0.3–0.7, p = < 
0.01) and fracture diagnosis (OR = 0.4, CI 0.2–0.9, p = 0.02) 
were the only signifi cant factors associated with not fi ling a 
claim for injury in a univariate logistic regression model (Table 
2). There was also a tendency toward higher rates of claims 
among female patients. When adjusted for age, sex, diagnosis, 
and level of education in the later multivariate model, they 
remained signifi cant, with similar OR, CI, and p-values.
The variation in claims between counties ranged between 
0% and 50%. Patients from smaller hospitals fi led claims 
more often, with the highest rates from the private hospitals 
(34%) and the lowest from university hospitals (16%) (p = 
0.06). We could not observe any statistically signifi cant cor-
relations between age of patients and claim rates from the dif-
ferent types of hospitals. Private hospitals operated only on 
patients with osteoarthritis (except 1 patient with femoral head 
necrosis).
44/112 (39%) claimants were compensated for prolonged 
recovery time and 64 (57%) for permanent disability, due to 
Table 1. Baseline data for all patients included in relation to claim 
of injury at LÖF. Values are number (percentage) unless otherwise 
stated
   
  All No claim Claim (25%)
   n = 441 n = 329 n = 112 p-value
Age, mean (SD) 70.7 (11) 71.8 (11) 67.4 (10) < 0.01
 distribution     
    < 50 15 (3) 10 (67) 5 (33) 
    51–60 66 (15) 45 (68) 21 (32) 
    61–70 116 (26) 78 (67) 38 (33) 
    71–80 167 (38) 126 (76) 41 (25) 
    > 80 77 (18) 70 (91) 7 (9) < 0.01
Sex    
 female 222 (50) 158 (71) 64 (29) 
 male 219 (50) 171 (78) 48 (22) 0.1
Diagnosis    
 primary osteoarthritis 328 (74) 236 (72) 92 (28) 
 hip fracture 67 (15) 58 (87) 9 (13) 
 other 46 (10) 35 (76) 11 (24) 0.04
Education    
 elementary school 205 (47) 161 (79) 44 (22) 
 high school 167 (38) 119 (71) 48 (29) 
 postgraduate 66 (15) 46 (79) 20 (30) 0.2
 unknown 3 (1) 3 (100) 0 (0) 
Hospitals    
 university 55 (13) 46 (84) 9 (16) 
 county 203 (46) 158 (78) 45 (22) 
 local 151 (34) 104 (69) 47 (31) 
 private 32 (7) 21 (66) 11 (34) 0.06
SD = standard deviation.
Table 2. Logistic regression to evaluate factors associated with insurance claim
 All Claim made Univariable  Multivariable
  n n (%) OR a (95%CI) p-value OR a (95%CI) RR b (95%CI) p-value
Age       
 < 73 years 224 74 (33) 1 (reference)  1 (reference)  
  73 years 217 38 (18) 0.4 (0.3–0.7) < 0.01 0.4 (0.3–0.7) 0.5 (0.4–0.8) < 0.01
Sex       
 male 219 48 (22) 1 (reference)    
 female 222 64 (29) 1.4 (0.9–2.2) 0.1     
Diagnosis       
 primary osteoarthritis 328 92 (28) 1 (reference)  1 (reference)  
 hip fracture 67 9 (13) 0.4 (0.2–0.8) 0.02 0.4 (0.2–0.8) 0.5 (0.3–0.8) 0.02
 other 46 11 (24) 0.8 (0.4–1.7) 0.6 0.7 (0.3–1.4) 0.8 (0.4–1.3) 0.3
Level of education c       
 elementary school 205 44 (22) 1 (reference)    
 secondary school 167 48 (29) 1.5 (0.9–2.4) 0.1   
 university 66 20 (30) 1.6 (0.9–3.0) 0.1     
a OR = odds ratio.
b RR = risk ratio.
c 3 missing values.
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PJI (Figure). There was an equal distribution of age groups 
within the 3 largest decision groups: recovery < 3 months, 
recovery > 3 months, and disability 1–15%.
Discussion
Our main fi nding was the high incidence of non-claimants and 
that almost all fi led claims were accepted for compensation 
by LÖF. This relation indicates on the one hand that those few 
patients who are claiming an injury from PJI are well informed 
about eligibility for compensation, but on the other hand it also 
suggests insuffi ciency of information from healthcare person-
nel to the large number of patients who do not make a claim. 
It is tempting to explain this by defi cient knowledge of the 
Patient Injury Act among the personnel. An explanation may 
be a scarce awareness of legal obligations concerning patients’ 
information. Another is a possible incorrect impression of the 
system not being blame-free for practitioners, with a follow-
ing unwillingness to report on colleagues if informing patients 
about LÖF. Third, in cases of fast and relatively complication-
free recovery, healthcare personnel may not inform patients 
based on their own judgment, an assumption of certain cases 
not being severe enough to generate compensation. There may 
also be other reasons contributing to not fi ling a claim; several 
of these have been discussed in previous publications (Sager 
et al. 1990, Studdert et al. 2000, Bismark et al. 2006, Järvelin 
et al. 2012, Zengerink et al. 2016).
Although intraoperative contamination and hematogenously 
spread infections are not specifi ed in our cohort, the prob-
ability of receiving compensation for PJI is high. We believe 
hematogenous spread was limited by the postoperative obser-
vation time and most PJIs are a result of IC (Zimmerli and 
Ochsner 2003, Azzam et al. 2010, Lee et al. 2010, Blomfeldt 
et al. 2015, Sendi et al. 2017). Additionally, 59% of claimants 
suffered a permanent disability, which also has a great impact 
on compensation. 
Age above 73 years and fracture diagnosis were the 2 signifi -
cant factors associated with lower rates of fi led claims. Higher 
rates of non-claimants in the elderly correspond to previous 
fi ndings (Sager et al. 1990, Studdert et al. 2000, Bismark et 
al. 2006, Järvelin et al. 2012, Zengerink et al. 2016). To our 
knowledge, specifi c claim rates of THR after fracture have not 
been studied previously. This fi nding suggests that healthcare 
personnel may be less prone to inform elderly patients, with 
possibly higher comorbidity, about the insurance.
Increased age and fracture diagnosis, possibly due to associ-
ated comorbidities, are associated with poorer outcome after 
treatment of PJI (Azzam et al. 2010, Blomfeldt et al. 2015). 
Our cohort included only 9 claimants who suffered a frac-
ture and did not allow for any further analysis. Age was not 
observed to affect LÖF’s decisions in our study. Since the 
overall incidence of claims was low, it is not possible to draw 
any conclusions concerning outcome after PJI in this popula-
tion. A possible explanation for our equal distribution of claim 
outcomes is that the more frail patients never fi led a claim.
Our fi nding of a trend among women to be more prone to 
fi ling a claim is supported by the earlier studies of claims after 
THR (Järvelin et al. 2012, Zengerink et al. 2016) and claims 
in the general population (Bismark et al. 2006).
Another trend is the higher rate of claimants among patients 
operated in private hospitals. Their population of elective 
patients, commonly healthier and more aware of their rights 
and entitlements, may explain this. The private units may also 
have a better dialogue with their patients, which could also be 
a contributive factor.
Swedish compensation is substantially lower than seen in 
Anglo-American tort systems but simpler for the claimants 
and with higher overall appeal success rates (50 vs. 30%) 
(Kachalia et al. 2008, Pukk-Härenstam et al. 2008). This fi nan-
cial difference can be explained partly by the lack of a puni-
tive component and partly by the existence of other forms of 
social insurance. The general support of the Swedish medical 
and social system may also diminish the economic importance 
of economic compensation. Additionally, elderly, injured, and 
often frail patients suffering from a PJI may refrain from fi ling 
claims due to perception of the process as diffi cult and long 
lasting. The fact of a free-of-charge, 2-page form and the rela-
tively short time to decision (70% within 8 months) (Kachalia 
et al. 2008) is not obvious to the general population. Finally, 
patients may not realize the blame-free nature of the insur-
ance. Some may refrain from claiming for their injury, as they 
are not willing to blame their doctor or department.
A limitation of our study is the inability to measure any 
rate of patient information about LÖF. We cannot conclude 
that non-claimants were not informed, nor can we assess the 
effi ciency of delivery or quality of given information. Another 
LÖF’s claims grouped by decisions (n) in the 112 claimed cases with 
distribution of age groups within.
Rejected Recovery
<3 months
Recovery
>3 months
Disability
1–15%
Disability
16–30%
Disability
> 30%
Age groups
< 50
51–60
61–70
71–80
>80
LÖF’s decision
Number of patients
60
50
40
30
20
10
0
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limitation is the inability to measure any correlation between 
clinical outcome of PJI treatment and the likelihood of claim-
ing injury. Additionally, we were not able to exclude hema-
togenously spread infections in our cohort beyond the limita-
tion of the 2-year postoperative observation period. Therefore 
the presence of any hematogenously spread infections among 
non-claimants cannot be assessed. However, there were no 
such infections among the claimants and none of the 4 cases 
were rejected due to the route of contamination. 
Nonetheless, we strongly suspect that most patients may not 
be aware that they have sustained an injury that is recognized 
by the healthcare system and possibly compensated by an 
insurance. It is therefore important to clearly inform patients 
suffering from PJI about their legal right to fi le a claim with 
LÖF and provide assistance when needed.
In summary our study shows that only every fourth PJI after 
THA is claimed as a patient injury. Simultaneously almost all 
claims were reimbursed by the Swedish national patient insur-
ance, indicating that patients who fi le claims are informed 
about their rights. The low claim rate suggests insuffi cient 
patient information and is of concern from both a legal and a 
professional aspect.
All authors contributed to the conception and design of the study, analysis 
of data and its interpretation, as well as revision of the manuscript. PK and 
AE performed the statistical analysis. 
Acta thanks Pieter K Bos and Jutta Järvelin for help with peer review of 
this study.
Azzam K A, Seeley M, Ghanem E, Austin M S, Purtill J J, Parvizi J. Irriga-
tion and debridement in the management of prosthetic joint infection: tradi-
tional indications revisited. J Arthroplasty 2010; 25(7): 1022-7.
Bismark M, Brennan T A, Davis P B, Studdert D M. Claiming behaviour in a 
no-fault system of medical injury: a descriptive analysis of claimants and 
non-claimants. Med J Aust 2006; 185(4): 203-7.
Blomfeldt R, Kasina P, Ottosson C, Enocson A, Lapidus L J. Prosthetic joint 
infection following hip fracture and degenerative hip disorder: a cohort 
study of three thousand, eight hundred and seven consecutive hip arthro-
plasties with a minimum follow-up of fi ve years. Int Orthop 2015; 39(11): 
2091-6.
Espersson C, Hellbacher U. Patientskadelagen – en kommentar m. m. Vulkan, 
Riga 2016.
IS. Insurance Sweden. Medicinsk Invaliditet –skador 2013. Insurance Sweden 
2014. Available from: http://www.svenskforsakring.se/globalassets/medi-
cinska-tabellverk/medicinska-tabellverk/medicinsk_invaliditet_skador_
rev_jan2014.pdf. 
Järvelin J, Häkkinen U, Rosenqvist G, Remes V. Factors predisposing to 
claims and compensations for patient injuries following total hip and knee 
arthroplasty. Acta Orthop 2012; 83(2): 190-6.
Kachalia A B, Mello M M, Brennan T A, Studdert D M. Beyond negligence: 
avoidability and medical injury compensation. Soc Sci Med 2008; 66(2): 
387-402.
Karrholm J, Lindahl H, Malchau H, Mohaddes M, Rogmark C, Rolfson O. 
Swedish Hip Arthroplasty Register: Annual Report 2015. Gothenburg, 
Sweden 2016. Available from: https://registercentrum.blob.core.windows.
net/shpr/r/Annual-Report-2015-H19dFINOW.pdf
Lee J, Kang C I, Lee J H, Joung M, Moon S, Wi Y M, Chung D R, Ha C W, 
Song J H, Peck K R. Risk factors for treatment failure in patients with 
prosthetic joint infections. J Hosp Infect 2010; 75(4): 273-6.
Lindgren V, Gordon M, Wretenberg P, Kärrholm J, Garellick G. Deep infec-
tion after total hip replacement: a method for national incidence surveil-
lance. Infect Control Hosp Epidemiol 2014; 35(12): 1491-6.
LÖF. Injury Report 2016. Anmälningar till LÖF 2016. Available from: http://
lof.se/wp-content/uploads/Statistik-2016-Hela-Sverige.pdf. Landstingens 
Ömsesidiga Försäkringsbolag; 2017.
Parvizi J, Zmistowski B, Berbari E F, Bauer T W, Springer B D, Della Valle C 
J, Garvin K L, Mont M A, Wongworawat M, Zalavras C G. New defi nition 
for periprosthetic joint infection: from the Workgroup of the Musculoskel-
etal Infection Society. Clin Orthop Rel Res 2011; 469(11): 2992-4.
Pukk-Härenstam K, Ask J, Brommels M, Thor J, Penaloza R V, Gaffney F 
A. Analysis of 23 364 patient-generated, physician reviewed malpractice 
claims from a non-tort, blamefree, national patient insurance system: les-
sons learned from Sweden. Qual Saf Health Care 2008; 17(4): 259-63.
Sager M, Voeks S, Drinka P, Langer E, Grimstad P. Do the elderly sue physi-
cians? Arch Intern Med 1990; 150(5): 1091-3.
Sendi P, Lotscher PO, Kessler B, Graber P, Zimmerli W, Clauss M. Debride-
ment and implant retention in the management of hip periprosthetic joint 
infection. Bone Joint J 2017; 99-B(3): 330-6.
Studdert D M, Thomas E J, Burstin H R, Zbar B I, Orav E J, Brennan T A. 
Negligent care and malpractice claiming behavior in Utah and Colorado. 
Med Care 2000; 38(3): 250-60.
SR-PIA. Sveriges Riksdag. Svensk författningssamling, Patientskad-
elag(1996:799) [The Swedish Parliament, Patient Injury Act], 2017:43. 
Available from: http://www.riksdagen.se/sv/dokument-lagar/dokument/
svensk-forfattningssamling/patientskadelag-1996799_sfs-1996-799.
SR-PSA. Sveriges Riksdag. Svensk författningssamling, Patientsäkerhet-
slag(2010:659). [The Swedish Parliament, Patient Safety Act], 2017:786. 
Available from: http://www.riksdagen.se/sv/dokument-lagar/dokument/
svensk-forfattningssamling/patientsakerhetslag-2010659_sfs-2010-659.
Zimmerli W, Oshsner P E. Management of infection associated with pros-
thetic joints. Infection 2003; 31(2): 99-108.
Zengerink I, Reijman M, Mathijssen N M, Eikens-Jansen M P, Bos P K. Hip 
arthroplasty malpractice claims in the Netherlands: closed claim study 
2000–2012. J Arthroplasty 2016; 31(9): 1890-3.
